000 03416nam a22004455i 4500
001 978-3-031-18903-6
003 DE-He213
005 20240729135856.0
007 cr nn 008mamaa
008 230104s2023 sz | s |||| 0|eng d
020 _a9783031189036
_9978-3-031-18903-6
024 7 _a10.1007/978-3-031-18903-6
_2doi
072 7 _aPSGL
_2bicssc
072 7 _aSCI099000
_2bisacsh
072 7 _aPSG
_2thema
100 1 _aMueller, Siguna.
_eauthor.
_4aut
_4http://id.loc.gov/vocabulary/relators/aut
245 1 0 _aChallenges and Opportunities of mRNA Vaccines Against SARS-CoV-2
_b : A Multidisciplinary Perspective /
250 _a1st ed. 2023.
264 1 _aCham :
_bSpringer International Publishing :
_bImprint: Springer,
_c2023.
300 _aXXXII, 439 p. 61 illus., 60 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
505 0 _aChapter 1: Introduction -- Part I: Scientifi Underpinnings, early expectations, and emerging challenges from the global inoculation experience -- Chapter 2: Appraisal of Some of the Key Postulates Underlying mRNA Vaccines -- Chapter 3: Relevance for mRNA vaccine safety -- Chapter 4: From Challenges to Opportunities and Open Questions -- Chapter 5: The challenge of evaluating vaccine safety and effectiveness -- Chapter 6: Safeguarding against the analog of antimicrobial-resistance development -- Chapter 7: Scales, pseudoscales, the human factor, and a way forward -- Part II: A deeper dive into mRNA vaccine safety and security, and developments until Delta -- Chapter 8: mRNA Vaccine safety and efficacy - official criteria when AEs are caused by the injection -- Chapter 9: mRNA Covid-19 vaccines best reflect effective pharmaceuticals - basic considerations and LNPs -- Chapter 10: mRNA Covid-19 pharmaceuticals and the spike antigen -- Chapter 11: Other facets of SARS-CoV-2 immunity, the risk of immune tolerance and T cell exhaustion -- Part III: The Omicron variants -- Chapter 12: Omicron -- Chapter 13: Conclusion.
520 _aThis book offers an analytical look at the much debated risks and benefits of the newly developed COVID-19 mRNA-vaccines. As such, it is one of the first books to give a comprehensive overview of mRNA vaccines against COVID-19 and the only one that addresses this topic from a broad multidisciplinary background. It brings together insights from various underlying disciplines on the challenges of developing and evaluating the most suitable vaccines for mass vaccination programs enrolled throughout the world - focusing on safety and efficacy. This book should not be missing on the shelf of any biomedical researcher, epidemiologist, public health professional or clinical researcher interested in SARS-CoV2 or virology and vaccine development in general. .
650 0 _aVirology.
_98273
650 0 _aMedical microbiology.
650 0 _aBiotechnology.
_95393
650 1 4 _aVirology.
_98273
650 2 4 _aMedical Microbiology.
650 2 4 _aBiotechnology.
_95393
710 2 _aSpringerLink (Online service)
856 _u#gotoholdings
_yAccess resource
912 _aZDB-2-SBL
912 _aZDB-2-SXB
245 _h[E-Book]
999 _c103347
_d103347